Marengo Therapeutics, an ATP company, is leading the development of a first-in-class immune activation platform that selectively activates and expands the right immune cells to mount potent anti-tumor responses for long-term protection against cancer.
Marengo antibodies induce targeted and durable anti-tumor activities in malignant solid tumor models and promote protective tumor immunity ("immune memory") while triggering unique cytokine release for the expansion of an antigen-specific memory T cell repertoire.
Marengo's lead project, a first-and-best-in-class therapy with single agent potential, is progressing to IND for advanced solid tumors. The company's versatile antibody discovery engine has also generated a pipeline of innovative antibody therapies with significant potential in several tumor types with high unmet medical needs.
